<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药魔方 | wechat-feeds</title><link>http://MzA4MDA4MTIzMg.favicon.privacyhide.com/favicon.ico</link><description>世事洞明皆学问，人情练达即文章</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 10 Jun 2021 10:22:40 +0800</pubDate><image><url>http://MzA4MDA4MTIzMg.favicon.privacyhide.com/favicon.ico</url><title>医药魔方 | wechat-feeds</title><link>http://MzA4MDA4MTIzMg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>里程碑！首个国产ADC药物获批！胃癌之外还有重大突破值得期待</title><link>https://mp.weixin.qq.com/s/zCwKQGmUXEquOSc4lTl9fw</link><description></description><content:encoded><![CDATA[里程碑！首个国产ADC药物获批！胃癌之外还有重大突破值得期待]]></content:encoded><pubDate>Thu, 10 Jun 2021 07:49:58 +0800</pubDate></item><item><title>全国药品带量采购进入“大合并”竞争时代！</title><link>https://mp.weixin.qq.com/s/kAZJoEkBvNHVPLH-YM43VA</link><description></description><content:encoded><![CDATA[全国药品带量采购进入“大合并”竞争时代！]]></content:encoded><pubDate>Thu, 10 Jun 2021 07:49:58 +0800</pubDate></item><item><title>免费通道！在BioChina，遇见创新者！</title><link>https://mp.weixin.qq.com/s/eOm4Q-R927kbarsocC24Fg</link><description></description><content:encoded><![CDATA[免费通道！在BioChina，遇见创新者！]]></content:encoded><pubDate>Thu, 10 Jun 2021 07:49:58 +0800</pubDate></item><item><title>BioBAY核酸药物研发论坛</title><link>https://mp.weixin.qq.com/s/SjX_wspFezi04iVkJXp_Hg</link><description></description><content:encoded><![CDATA[BioBAY核酸药物研发论坛]]></content:encoded><pubDate>Thu, 10 Jun 2021 07:49:58 +0800</pubDate></item><item><title>欧加隆重出江湖，能否再次打响女性健康领域的百年品牌？</title><link>https://mp.weixin.qq.com/s/LimcmoyewL0M-Up-B_v4jA</link><description></description><content:encoded><![CDATA[欧加隆重出江湖，能否再次打响女性健康领域的百年品牌？]]></content:encoded><pubDate>Wed, 09 Jun 2021 07:25:01 +0800</pubDate></item><item><title>国内首个！乐普生物TF ADC提交中国新药临床申请</title><link>https://mp.weixin.qq.com/s/XN9lJdqPFMRByb0VW-W5RA</link><description></description><content:encoded><![CDATA[国内首个！乐普生物TF ADC提交中国新药临床申请]]></content:encoded><pubDate>Wed, 09 Jun 2021 07:25:01 +0800</pubDate></item><item><title>恒瑞医药64项研究入选ASCO年会，卡瑞利珠单抗力撑“半壁江山”</title><link>https://mp.weixin.qq.com/s/IPfiAA-Q2C-UjOaJIWZN5Q</link><description></description><content:encoded><![CDATA[恒瑞医药64项研究入选ASCO年会，卡瑞利珠单抗力撑“半壁江山”]]></content:encoded><pubDate>Wed, 09 Jun 2021 07:25:01 +0800</pubDate></item><item><title>德琪医药合作伙伴公布Eltanexor治疗去甲基化药物难治的骨髓增生异常综合征的最新临床数据</title><link>https://mp.weixin.qq.com/s/KgsRkK-OwGJ3_CcoLlnGaw</link><description></description><content:encoded><![CDATA[德琪医药合作伙伴公布Eltanexor治疗去甲基化药物难治的骨髓增生异常综合征的最新临床数据]]></content:encoded><pubDate>Wed, 09 Jun 2021 07:25:01 +0800</pubDate></item><item><title>倒计时10天！BioChina大会即将开幕</title><link>https://mp.weixin.qq.com/s/4yDgVKKPDeUpA1T-SJ__Hw</link><description></description><content:encoded><![CDATA[倒计时10天！BioChina大会即将开幕]]></content:encoded><pubDate>Wed, 09 Jun 2021 07:25:01 +0800</pubDate></item><item><title>诺华first in class口服 IgA 肾病新药II 期研究达到主要终点</title><link>https://mp.weixin.qq.com/s/cdujqbAQLFtRLrS_hUH4Sg</link><description></description><content:encoded><![CDATA[诺华first in class口服 IgA 肾病新药II 期研究达到主要终点]]></content:encoded><pubDate>Tue, 08 Jun 2021 07:56:51 +0800</pubDate></item><item><title>FDA批准Biogen阿尔茨海默症新药aducanumab</title><link>https://mp.weixin.qq.com/s/SIrF-hpVpH_1oIDXr8QxCw</link><description></description><content:encoded><![CDATA[FDA批准Biogen阿尔茨海默症新药aducanumab]]></content:encoded><pubDate>Tue, 08 Jun 2021 07:56:51 +0800</pubDate></item><item><title>EGFR T790M一线疗法对比：阿美替尼 vs 奥希替尼</title><link>https://mp.weixin.qq.com/s/GM8CJDqLItAOJG7E_L-unw</link><description></description><content:encoded><![CDATA[EGFR T790M一线疗法对比：阿美替尼 vs 奥希替尼]]></content:encoded><pubDate>Tue, 08 Jun 2021 07:56:51 +0800</pubDate></item><item><title>晚期食管癌一线治疗：前有虎狼，后有追兵</title><link>https://mp.weixin.qq.com/s/sPe9jNtbquMWzNusYLrpDw</link><description></description><content:encoded><![CDATA[晚期食管癌一线治疗：前有虎狼，后有追兵]]></content:encoded><pubDate>Tue, 08 Jun 2021 07:56:51 +0800</pubDate></item><item><title>亚盛医药Bcl-2抑制剂治疗R/R CLL/SLL最新数据公布：ORR达80%</title><link>https://mp.weixin.qq.com/s/NLaLM_GJKBPe69NRM57-_g</link><description></description><content:encoded><![CDATA[亚盛医药Bcl-2抑制剂治疗R/R CLL/SLL最新数据公布：ORR达80%]]></content:encoded><pubDate>Tue, 08 Jun 2021 07:56:51 +0800</pubDate></item><item><title>紧随前局长！FDA“2号”加盟谷歌子公司</title><link>https://mp.weixin.qq.com/s/Zsiszsvb1v4FFUvQT5hIwg</link><description></description><content:encoded><![CDATA[紧随前局长！FDA“2号”加盟谷歌子公司]]></content:encoded><pubDate>Tue, 08 Jun 2021 07:56:51 +0800</pubDate></item><item><title>直播预告 | ASCO 2021最值得关注Top10新机会深度解析</title><link>https://mp.weixin.qq.com/s/DLSJEf6yhWqBE01OLJtXUg</link><description></description><content:encoded><![CDATA[直播预告 | ASCO 2021最值得关注Top10新机会深度解析]]></content:encoded><pubDate>Tue, 08 Jun 2021 07:56:51 +0800</pubDate></item><item><title>“中国研究”首次入选ASCO全体大会！特瑞普利单抗鼻咽癌研究有望改写国际标准</title><link>https://mp.weixin.qq.com/s/14DIhvJAO02HoYPNFGWbKA</link><description></description><content:encoded><![CDATA[“中国研究”首次入选ASCO全体大会！特瑞普利单抗鼻咽癌研究有望改写国际标准]]></content:encoded><pubDate>Mon, 07 Jun 2021 07:40:31 +0800</pubDate></item><item><title>乐普生物差异化PD-1单抗，临床优势初显</title><link>https://mp.weixin.qq.com/s/o4m5xFSaOiddJacN-w12Uw</link><description></description><content:encoded><![CDATA[乐普生物差异化PD-1单抗，临床优势初显]]></content:encoded><pubDate>Mon, 07 Jun 2021 07:40:31 +0800</pubDate></item><item><title>博安生物博优诺®（贝伐珠单抗注射液）正式上市，患者救助项目同步启动</title><link>https://mp.weixin.qq.com/s/dv2xWLpCwSb6wUW37dWqfA</link><description></description><content:encoded><![CDATA[博安生物博优诺®（贝伐珠单抗注射液）正式上市，患者救助项目同步启动]]></content:encoded><pubDate>Mon, 07 Jun 2021 07:40:31 +0800</pubDate></item><item><title>武田、迪哲、再鼎、杨森「同台竞技」，EGFR exon20抑制剂哪家强？</title><link>https://mp.weixin.qq.com/s/Xp_4KK7Bs1HfsSQnehxS_w</link><description></description><content:encoded><![CDATA[武田、迪哲、再鼎、杨森「同台竞技」，EGFR exon20抑制剂哪家强？]]></content:encoded><pubDate>Mon, 07 Jun 2021 07:40:31 +0800</pubDate></item></channel></rss>